Brokerages expect Gemphire Therapeutics Inc. (NASDAQ:GEMP) to report ($0.80) earnings per share (EPS) for the current fiscal quarter, Zacks reports. Zero analysts have issued estimates for Gemphire Therapeutics’ earnings. Gemphire Therapeutics reported earnings of ($0.42) per share during the same quarter last year, which indicates a negative year over year growth rate of 90.5%. The business is scheduled to report its next quarterly earnings report on Wednesday, September 13th.

According to Zacks, analysts expect that Gemphire Therapeutics will report full-year earnings of ($2.78) per share for the current fiscal year. For the next fiscal year, analysts forecast that the business will report earnings of ($2.04) per share. Zacks Investment Research’s earnings per share calculations are an average based on a survey of sell-side research analysts that that provide coverage for Gemphire Therapeutics.

Gemphire Therapeutics (NASDAQ:GEMP) last announced its quarterly earnings data on Tuesday, May 9th. The company reported ($0.79) EPS for the quarter, missing the consensus estimate of ($0.61) by $0.18.

A number of equities research analysts have commented on GEMP shares. Zacks Investment Research upgraded shares of Gemphire Therapeutics from a “sell” rating to a “hold” rating in a research note on Thursday, May 11th. Canaccord Genuity restated a “buy” rating and set a $17.00 target price on shares of Gemphire Therapeutics in a research note on Wednesday, May 31st. Piper Jaffray Companies initiated coverage on shares of Gemphire Therapeutics in a research report on Monday, April 10th. They set an “overweight” rating and a $30.00 price objective on the stock. Finally, Jefferies Group LLC set a $17.00 price objective on shares of Gemphire Therapeutics and gave the company a “buy” rating in a research report on Wednesday, May 31st. One research analyst has rated the stock with a hold rating and five have given a buy rating to the company’s stock. Gemphire Therapeutics currently has a consensus rating of “Buy” and a consensus target price of $21.80.

ILLEGAL ACTIVITY WARNING: This article was originally published by The Cerbat Gem and is the property of of The Cerbat Gem. If you are reading this article on another website, it was stolen and republished in violation of international copyright laws. The correct version of this article can be accessed at https://www.thecerbatgem.com/2017/08/03/zacks-analysts-expect-gemphire-therapeutics-inc-gemp-will-announce-earnings-of-0-80-per-share-updated-updated-updated.html.

Several large investors have recently added to or reduced their stakes in the stock. Norris Perne & French LLP MI bought a new stake in Gemphire Therapeutics during the first quarter valued at about $110,000. Renaissance Technologies LLC bought a new stake in Gemphire Therapeutics during the first quarter valued at about $184,000. Exchange Capital Management Inc. bought a new stake in Gemphire Therapeutics during the first quarter valued at about $444,000. Finally, Cambridge Investment Research Advisors Inc. bought a new stake in Gemphire Therapeutics during the first quarter valued at about $1,581,000. Hedge funds and other institutional investors own 27.77% of the company’s stock.

Shares of Gemphire Therapeutics (GEMP) traded up 0.31% during mid-day trading on Thursday, reaching $13.05. 62,043 shares of the company’s stock traded hands. The stock’s market cap is $138.33 million. Gemphire Therapeutics has a 12-month low of $7.25 and a 12-month high of $13.98. The firm’s 50 day moving average price is $10.89 and its 200-day moving average price is $10.24.

About Gemphire Therapeutics

Gemphire Therapeutics Inc is a clinical-stage biopharmaceutical company. The Company is engaged in the development and commercialization of therapeutics to treat cardiovascular and metabolic diseases. It is developing its product candidate, gemcabene (CI-1027), which is a once-daily, oral therapy for patients who are unable to achieve normal levels of low-density lipoprotein cholesterol (LDL-C) or triglycerides with approved therapies, primarily statin therapy.

Get a free copy of the Zacks research report on Gemphire Therapeutics (GEMP)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Stock Ratings for Gemphire Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Gemphire Therapeutics Inc. and related stocks with our FREE daily email newsletter.